Conditions: Alzheimer's Disease
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 103
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: ELND005 (scyllo-inositol)
Intervention descriptions: intervention 1: Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks

After 15Dec2009: ELND005 250 mg PO BID for 48 weeks

Protocol document: